Prevent Cardiac Surgery Associated AKI Trial

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Renal Failure, Coronary Artery Disease, Surgery, Surgery-Complications

In brief

Prevent CSA-AKI (Cardiac Surgery Associated Acute Kidney Injury) trial is a double blinded randomized controlled trial, 242 patients undergoing elective cardiopulmonary bypass surgery (CPB)will either receive a placebo or daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH), the first dose will be given the day before surgery and continues while admitted up to 1 week. Blood and urine samples will be collected. Adverse events related to the study drugs will be collected.

Key facts

Study ID

NCT06620523

Run by

George Washington University

People needed

242

Starts

2024-07-18

Expected to finish

2028-06-17

Last updated by the study team

2025-10-08

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult 18-70 years of age
• Undergoing elective CPB (Cardiopulmonary Bypass) surgery
• Baseline GFR (Glomerular Filtration Rate) ≥45 ml/min

You may not qualify if…

• GFR (Glomerular Filtration Rate) <45 ml/min
• Solitary kidney
• Status post-kidney transplant
• Pregnant women
• Allergy to CoQ10
• Allergy to Glutathione
• Allergy to Cellulose

Where it is running

• George Washington University Hospital — Washington D.C., District of Columbia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.